RECHERCHE :   Cancers du poumon - cancers thoraciques
Filtrage ? Le champ de filtrage permet de trier les études comportant le mot saisie. La recherche du mot se fait uniquement dans le contenu texte affiché à l'écran.
ETUDE PHASE SITE
AMGEN 20160323: A Phase 1 Study Evaluating the Safety, Tolerability and Pharmacokinetics of AMG 757 in Subjects With Small Cell Lung Cancer
cancer du poumon à petites cellules
I
CHUV
Amgen 20200491: A Phase 2 Study Evaluating the Efficacy, Safety, Tolerability, and Pharmacokinetics of Tarlatamab in Subjects with Relapsed/Refractory Small Cell Lung Cancer After Two or More Prior Lines of Treatment
Relapsed/Refractory SCLC
II
HUG
BMS CA022-001: Phase 1/2a First-In-Human Study of BMS-986218 Monoclonal Antibody Alone and in Combination with Nivolumab in Advanced Solid Tumors
Tumeurs solides avancées
I, II
CHUV
BMS CA209-73L: A Phase 3, Randomized, Open Label Study to Compare Nivolumab plus Concurrent Chemoradiotherapy (CCRT) followed by Nivolumab plus Ipilimumab or Nivolumab plus CCRT Followed by Nivolumab vs CCRT followed by Durvalumab in Previously Untreated, Locally Advanced Non-small Cell Lung Cancer
cancer du poumon non à petites cellules localement avancé n’ayant jamais été traité
III
CHUV
CA027-002: A Phase 1/2a Study of BMS-986253 in Combination with Nivolumab or Nivolumab plus Ipilimumab in Advanced Cancers
Tumeurs solides avancés
I, II
CHUV
BMS CA224-048: A Phase 1/2 Study of Relatlimab (anti-LAG-3 Monoclonal Antibody) Administered in Combination with Both Nivolumab (anti-PD-1 Monoclonal Antibody) and BMS- 986205 (IDO1 inhibitor) or in Combination with Both Nivolumab and Ipilimumab (anti-CTLA-4 Monoclonal Antibody) in Advanced Malignant Tumors
Tumeurs solides (Mélanome, Cancer du poumon non à petites cellules (NSCLC))
I, II
CHUV
CACZ885T2301: A phase III, multicenter, randomized, double blind, placebocontrolled study evaluating the efficacy and safety of canakinumab versus placebo as adjuvant therapy in adult subjects with stages AJCC/UICC v. 8 II-IIIA and IIIB (T>5cm N2) completely resected (R0) non-small cell lung cancer (NSCLC)
Cancer bronchique non à petites cellules complètement réséqué, stade II à IIIA et IIIB
III
HUG
ETOP 15-19: A randomised non-comparative open label phase II trial of atezolizumab plus bevacizumab, with carboplatin-paclitaxel or pemetrexed, in EGFR-mutant NSCLC with acquired resistance
EGFR-mutant NSCLC with acquired resistance
II
HUG
IOSI-LUNG-001: Atezolizumab plus 8 Gy single-fraction radiotherapy for advanced, oligoprogressive NSCLC after upfront chemotherapy and anti-PD1 immunotherapy: A multicentre, single arm, phase II study
Advanced and oligoprogressive NSCLC
II
HUG
CHUV-DO-0022-LUNGVAC-2019: Phase Ib study to test the feasibility and safety of a personalized vaccine in combination with low-dose cyclophosphamide in patients with advanced or metastatic NSCLC
NSCLC avancé ou métastatique
I
CHUV
MK3475-867: A Phase 3, Randomized, Placebo-Controlled Clinical Study to Evaluate the Safety and Efficacy of Stereotactic Body Radiotherapy (SBRT) with or without Pembrolizumab (MK-3475) in Participants with Medically Inoperable Stages I or IIA Non Small Cell Lung Cancer (NSCLC) (KEYNOTE-867)
Medically inoperable NSCLC Stages I and IIA
III
HUG
CHUV-DO-0018-NeoTIL-2019: Pilot Study to Assess the Feasibility, Safety and Efficacy of Adoptive Transfer of Autologous Tumor-Infiltrating Lymphocytes Enriched for Tumor Antigen Specificity (NeoTIL) in Advanced Solid Tumors.
Tumeurs solides
I
CHUV
SAKK 15/19: Thoracic radiotherapy plus maintenance Durvalumab after first line Carboplatin and Etoposide plus Durvalumab in ED-SCLC. A multicenter single arm open label phase II trial
extensivestage disease small cell lung cancer
II
HUG
SAKK16/18: Immune-modulatory radiotherapy to enhance the effects of neoadjuvant PD-L1 blockade after neoadjuvant chemotherapy in patients with resectable stage III(N2) NSCLC. A multicenter phase II trial.
resectable stage III(N2) NSCLC
II
HUG
ZEAL-1L/GSK 213400: Placebo-controlled Study Comparing Niraparib Plus Pembrolizumab Versus Placebo Plus Pembrolizumab as Maintenance Therapy in Participants with Advanced/Metastatic Non-Small Cell Lung Cancer
cancer du poumon non à petites cellules avancé
III
CHUV